Related Experiment Video
Updated: Feb 9, 2026

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
Published on: January 9, 2018
Tumor immunotherapy: New aspects of natural killer cells
1Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, China.
Abstract:
A group of impressive immunotherapies for cancer treatment, including immune checkpoint-blocking antibodies, gene therapy and immune cell adoptive cellular immunotherapy, have been established, providing new weapons to fight cancer. Natural killer (NK) cells are a component of the first line of defense against tumors and virus infections. Studies have shown dysfunctional NK cells in patients with cancer. Thus, restoring NK cell antitumor functionality could be a promising therapeutic strategy. NK cells that are activated and expanded ex vivo can supplement malfunctional NK cells in tumor patients. Therapeutic antibodies, chimeric antigen receptor (CAR), or bispecific proteins can all retarget NK cells precisely to tumor cells. Therapeutic antibody blockade of the immune checkpoints of NK cells has been suggested to overcome the immunosuppressive signals delivered to NK cells. Oncolytic virotherapy provokes antitumor activity of NK cells by triggering antiviral immune responses. Herein, we review the current immunotherapeutic approaches employed to restore NK cell antitumor functionality for the treatment of cancer.
Insights
Restoring natural killer (NK) cell antitumor functionality is a promising cancer treatment strategy. Activated NK cells, enhanced by therapies like CARs and checkpoint blockade, can effectively target and eliminate tumors.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Natural killer (NK) cells are crucial for innate immunity against tumors and viral infections.
- Dysfunctional NK cells are observed in cancer patients, highlighting the need to restore their antitumor activity.
- Current immunotherapies offer new avenues for cancer treatment.
Purpose of the Study:
- To review current immunotherapeutic strategies aimed at restoring NK cell antitumor functionality for cancer treatment.
- To explore how NK cell-based therapies can overcome tumor-induced immunosuppression.
Main Methods:
- Review of existing literature on immunotherapies targeting NK cells.
- Analysis of approaches including immune checkpoint blockade, gene therapy, and adoptive cellular immunotherapy.
- Examination of therapeutic antibodies, chimeric antigen receptors (CARs), and bispecific proteins for NK cell retargeting.
- Discussion of oncolytic virotherapy's role in stimulating NK cell activity.
Main Results:
- Activated and expanded NK cells ex vivo can supplement deficient NK cells in cancer patients.
- Therapeutic antibodies, CARs, and bispecific proteins enable precise NK cell targeting of tumor cells.
- Immune checkpoint blockade and oncolytic virotherapy can enhance NK cell-mediated antitumor responses.
Conclusions:
- Restoring NK cell antitumor functionality represents a promising therapeutic strategy for cancer.
- Various immunotherapeutic approaches, including engineered NK cells and immune modulation, show potential in enhancing cancer treatment outcomes.
Related Concept Videos
Tumor Immunotherapy
What is Natural Selection?
Nature and Nurture
Quantitative Aspects of Drug-Receptor Interaction
Chirality in Nature
The Wave Nature of Light

